semaglutide ivim GLP1ID-HFD-A – Ivím Health Ivim Health Tirzepatide Review: How

Pistollato F, Forbes-Hernndez TY, Caldern Iglesias R, Ruiz R, Elexpuru Zabaleta M, Cianciosi D, et al

Always feel free to substitute in a way that works for you

At 40 weeks, participants saw average A1C reductions of: 1.3% with the low dose 1.6% with the middle dose 1.5% with the high dose This compares to a 0.1% reduction in the placebo group

Yet peer-reviewed evidence for their effectiveness is vanishingly thin

Therefore, this review aims to synthesize the evidence on the mechanistic expansion of GLP-1RAs from metabolic regulators to systemic modulators of inflammation, autophagy, and organ protection, and explores their therapeutic repurposing across diseases